Evidence of micro-and macro-thrombi in the arteries and veins of critically ill COVID-19
patients and in autopsies highlight the occurrence of COVID-19-associated coagulopathy …

The observations that traditional cardiovascular disease (CVD) risk factors fail to fully
account for the excessive cardiovascular mortality in patients with systemic lupus …

Arterial and venous thrombosis constitutes a major source of morbidity and mortality
worldwide. Long considered as distinct entities, accumulating evidence indicates that …

To reveal if coagulopathies relate to the course of COVID-19, we examined 255 patients with
moderate and severe COVID-19, receiving anticoagulants and immunosuppressive drugs …

Pathological eye involvement represents a quite common finding in a broad spectrum of
autoimmune rheumatic diseases (ARDs). Ocular signs, often occur as early manifestations …

Antiphospholipid syndrome is one of the more common acquired causes of
hypercoagulability. Its major presentations are thrombotic (arterial, venous, or …

Antiphospholipid syndrome (APS) is a systemic autoimmune condition characterised by the
presence of antiphospholipid antibodies (aPL) associated with vascular thrombosis and/or …

Primary antiphospholipid syndrome (PAPS) is a systemic autoimmune disease associated
with recurrent thrombosis and/or obstetric morbidity with persistent antiphospholipid …

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by venous,
arterial, or small‐vessel thrombosis and/or pregnancy‐related morbidity, associated with …

Antiphospholipid antibody (aPL)-persistent positivity is frequent in hemodialysis (HD)
patients. Native arteriovenous fistula (AVF) complications such as stenosis and thrombosis …